Alcresta’s RELiZORB shows BMI and weight gains in pediatric tube-fed patients
See how RELiZORB improved weight and BMI z-scores in tube-fed children aged 1–5 in new real-world data. Explore what this means for pediatric care today.
Can ELEVIDYS meet its promise? Sarepta’s pivotal Duchenne gene therapy trial nears major milestone
Sarepta’s EMBARK 3-year readout could clarify ELEVIDYS’ long-term role in Duchenne care. Find out what’s at stake in this pivotal gene therapy trial.
JAMA validates nalbuphine ER’s efficacy in IPF chronic cough as Trevi eyes next steps
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.
RED-C setback for Bausch Health: What this failed Phase 3 trial reveals about cirrhosis care gaps
Bausch’s RED-C trial failed to meet endpoints in hepatic encephalopathy prevention. Find out what this means for rifaximin SSD’s future and the field.
How ImmunityBio’s ANKTIVA combo is challenging glioblastoma’s immune collapse model
New Phase 2 data suggest ImmunityBio’s ANKTIVA plus CAR-NK combo could restore immune competence in glioblastoma. Find out why it matters.
Is deceased donor marrow a viable backup graft? First human data from Ossium says yes
Ossium unveils early data on cryopreserved cadaveric marrow in transplants. Find out what this could mean for urgent graft availability.
Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.
Brazil rollout puts Bavarian Nordic’s chikungunya vaccine under regulatory and execution scrutiny
Find out how Bavarian Nordic’s Brazil rollout with Eurofarma puts its chikungunya vaccine to the ultimate regulatory and execution test.
Vaxcyte advances VAX-31 as Phase 3 trial design choices highlight regulatory and adoption priorities
Vaxcyte advances VAX-31 into pivotal adult and infant studies. Find out how trial design choices shape regulatory and adoption outcomes.
How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis
Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.